Clinical Trial Update: Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 double-blind, multicenter, sham-surgery controlled trial of CERE-120 in idiopathic Parkinson's disease has completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• CERE-120

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Idiopathic Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2012-08-14